Recursion Pharmaceuticals, Inc.

RXRX · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders2.3%

Institutions70.6%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$74.68M	$58.84M	$44.58M	$39.84M	$10.18M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$70.95M	$45.24M	$42.59M	$48.27M	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$648.13M	-$479.00M	-$350.06M	-$245.73M	-$182.78M
Operating income as a percentage of revenue.	-867.9%	-814.1%	-785.3%	-616.7%	-1795.8%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$644.76M	-$463.66M	-$328.07M	-$239.48M	-$186.48M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.44	$-1.69	$-1.58	$-1.00	$-1.49
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.44	$-1.69	$-1.58	$-1.00	$-1.49

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$743.29M	$594.35M	$391.56M	$549.91M	$285.12M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$1.47B	$1.45B	$653.70M	$701.29M	$610.35M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	$41000	$97000	$90000
Everything the company owes — debt, unpaid bills, and other obligations.	$343.26M	$413.82M	$190.26M	$215.48M	$67.41M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$1.13B	$1.03B	$463.44M	$485.81M	$542.94M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$371.81M	-$359.17M	-$287.78M	-$83.52M	-$158.61M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$6.47M	$13.70M	$11.96M	$37.06M	$39.80M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$378.28M	-$372.87M	-$299.74M	-$120.58M	-$198.41M

	You	Peer avg
Revenue Growth	-60.1%	+120.5%
ROE	-56.6%	-132.4%

Recursion Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison